A White House panel issued a report Tuesday urging several steps designed to curb rising prices for cancer medications, notably a recommendation for determining value for these increasingly expensive treatments, which can cost $100,000 or more a year.
“The panel concluded that misalignment of drug prices and value is a critical problem that must be addressed,” wrote the three-member panel, an advisory group created under President Nixon in 1971. “Achieving better alignment could improve the quality of cancer care; create incentives for development of innovative, effective new drugs; and help address increases in drug spending that are threatening to put high-value drugs out of reach for some patients.”
About the Author Reprints
